Enhanced anti-tumor immunotherapy by silica-coated magnetic nanoparticles conjugated with ovalbumin

References

• Shin WJ, Noh HJ, Noh YW, Kim S, Um SH, Lim YT. Hyaluronic acid-supported combination of water insoluble immunostimulatory compounds for anti-cancer immunotherapy. Carbohydr Polym. 2017;155:1–10. doi:10.1016/j.carbpol.2016.08.04027702491
   PubMed Web of Science ®Google Scholar
• Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol. 2009;27:83–117. doi:10.1146/annurev.immunol.021908.13254419007331
   PubMed Web of Science ®Google Scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480–489. doi:10.1038/nature1061122193102
   PubMed Web of Science ®Google Scholar
• Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nature Rev Immunol. 2007;7(10):790–802. doi:10.1038/nri217317853902
   PubMed Web of Science ®Google Scholar
• Kim JJ, Hwang YH, Kang KY, et al. Enhanced dendritic cell maturation by the B-chain of Korean mistletoe lectin (KML-B), a novel TLR4 agonist. Int Immunopharmacol. 2014;21(2):309–319. doi:10.1016/j.intimp.2014.05.01024859056
   PubMedGoogle Scholar
• Han HD, Byeon Y, Jang JH, et al. In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy. Sci Rep. 2016;6:38348. doi:10.1038/srep3834827910914
   PubMed Web of Science ®Google Scholar
• Eggermont LJ, Paulis LE, Tel J, Figdor CG. Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells. Trends Biotechnol. 2014;32(9):456–465. doi:10.1016/j.tibtech.2014.06.00724998519
   PubMed Web of Science ®Google Scholar
• Kim J, Mooney DJ. In vivo modulation of dendritic cells by engineeredmaterials: towards new cancer vaccines. Nano Today. 2011;6(5):466–477. doi:10.1016/j.nantod.2011.08.00522125572
   PubMedGoogle Scholar
• Li WA, Mooney DJ. Materials based tumor immunotherapy vaccines. Curr Opin Immunol. 2013;25(2):238–245. doi:10.1016/j.coi.2012.12.00823337254
   PubMedGoogle Scholar
• Song C, Noh YW, Lim YT. Polymer nanoparticles for cross-presentation of exogenous antigens and enhanced cytotoxic T-lymphocyte immune response. Int J Nanomed. 2016;11:3753–3764. doi:10.2147/IJN.S110796
   PubMed Web of Science ®Google Scholar
• Friede M, Aguado MT. Need for new vaccine formulations and potential of particulate antigen and DNA delivery systems. Adv Drug Deliv Rev. 2005;57(3):325–331. doi:10.1016/j.addr.2004.10.00115560944
   PubMedGoogle Scholar
• Heo MB, Lim YT. Programmed nanoparticles for combined immunomodulation, antigen presentation and tracking of immunotherapeutic cells. Biomaterials. 2014;35(1):590–600. doi:10.1016/j.biomaterials.2014.01.02624125775
   PubMedGoogle Scholar
• Noh YW, Hong JH, Shim SM, et al. Polymer nanomicelles for efficient mucus delivery and antigen-specific high mucosal immunity. Angew Chem Int Ed Engl. 2013;52(30):7684–7689. doi:10.1002/anie.20130288123765547
   PubMedGoogle Scholar
• Serda RE. Particle platforms for cancer immunotherapy. Int J Nanomed. 2013;8:1683–1696. doi:10.2147/IJN.S37465
   PubMed Web of Science ®Google Scholar
• Kim BS, Chun SY, Lee JK, et al. Human amniotic fluid stem cell injection therapy for urethral sphincter regeneration in an animal model. BMC Med. 2012;10:94. doi:10.1186/1741-7015-10-9422906045
   PubMedGoogle Scholar
• Park JS, Na K, Woo DG, et al. Non-viral gene delivery of DNA polyplexed with nanoparticles transfected into human mesenchymal stem cells. Biomaterials. 2010;31(1):124–132. doi:10.1016/j.biomaterials.2009.09.02319818490
   PubMedGoogle Scholar
• Kim JS, Yoon TJ, Yu KN, et al. Toxicity and tissue distribution of magnetic nanoparticles in mice. Toxicol Sci. 2006;89(1):338–347. doi:10.1093/toxsci/kfj02716237191
   PubMed Web of Science ®Google Scholar
• Park KS, Tae J, Choi B, et al. Characterization, in vitro cytotoxicity assessment, and in vivo visualization of multimodal, RITC-labeled, silica-coated magnetic nanoparticles for labeling human cord blood-derived mesenchymal stem cells. Nanomedicine. 2010;6(2):263–276. doi:10.1016/j.nano.2009.07.00519699324
   PubMedGoogle Scholar
• Lee JK, Chun SY, Im JY, Jin HK, Kwon TG, Bae JS. Specific labeling of neurogenic, endothelial, and myogenic differentiated cells derived from human amniotic fluid stem cells with silica-coated magnetic nanoparticles. J Vet Med Sci. 2012;74(8):969–975. doi:10.1292/jvms.12-001622446399
   PubMedGoogle Scholar
• Yoon TJ, Kim JS, Kim BG, Yu KN, Cho MH, Lee JK. Multifunctional nanoparticles possessing a “magnetic motor effect” for drug or gene delivery. Angew Chem Int Ed Engl. 2005;44(7):1068–1071. doi:10.1002/anie.20046191015635729
   PubMed Web of Science ®Google Scholar
• Kim JJ, Nam JP, Nah JW, Jang MK, Yee ST. Immunoadjuvant efficacy of N-carboxymethyl chitosan for vaccination via dendritic cell activation. J Med Food. 2014;17(2):268–277. doi:10.1089/jmf.2013.292124325456
   PubMedGoogle Scholar
• Kim JJ, Hwang YH, Kang KY, et al. Antitumor effect of KML-B-treated dendritic cells via induction of lymphocyte activation. J Immunol Res. 2017;2017:2471627. doi:10.1155/2017/597457428634588
   PubMedGoogle Scholar
• Lee SJ, Kim JJ, Kang KY, et al. Herbal preparation (HemoHIM) enhanced functional maturation of bone marrow-derived dendritic cells mediated toll-like receptor 4. BMC Complement Altern Med. 2016;16:67. doi:10.1186/s12906-016-1045-926891999
   PubMed Web of Science ®Google Scholar
• Kim SY, Phuengkham H, Noh YW, Lee HG, Um SH, Lim YT. Immune complexes mimicking synthetic vaccine nanoparticles for enhanced migration and cross-presentation of dendritic cells. Adv Funct Mater. 2016;26(44):8072–8082. doi:10.1002/adfm.201603651
   Web of Science ®Google Scholar
• Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell. 1988;54:777–785. doi:10.1016/s0092-8674(88)91043-43261634
   PubMed Web of Science ®Google Scholar
• Shim W, Paik MJ, Nguyen DT, et al. Analysis of changes in gene expression and metabolic profiles induced by silica-coated magnetic nanoparticles. ACS Nano. 2012;6(9):7665–7680. doi:10.1021/nn301113f22830605
   PubMedGoogle Scholar
• Phukan G, Shin TH, Shim JS, et al. Silica-coated magnetic nanoparticles impair proteasome activity and increase the formation of cytoplasmic inclusion bodies in vitro. Sci Rep. 2016;6:290095. doi:10.1038/srep29095
   Web of Science ®Google Scholar
• Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3:133–146. doi:10.1038/nri100112563297
   PubMed Web of Science ®Google Scholar
• Ko BK, Lee SY, Lee YH, et al. Combination of novel HER2-targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2-positive gastric cancer. Mol Oncol. 2015;9:398–408. doi:10.1016/j.molonc.2014.09.00725306393
   PubMed Web of Science ®Google Scholar
• An M, Li M, Xi J, Liu H, Liu H. Silica nanoparticle as a lymph node targeting platform for vaccine delivery. ACS Appl Mater Interfaces. 2017;9(28):23466–23475. doi:10.1021/acsami.7b0602428640587
   PubMed Web of Science ®Google Scholar
• Yang HL, Zhao JL, Wu CY, Ye CQ, Zou DW, Wang SG. Facile synthesis of colloidal stable MoS2 nanoparticles for combined tumor therapy. Chem Eng J. 2018;351:548–558. doi:10.1016/j.cej.2018.06.100
   Web of Science ®Google Scholar
• Zhao J, Xie P, Ye C, et al. Outside-in synthesis of mesoporous silica/molybdenum disulfide nanoparticles for antitumor application. Chem Eng J. 2018;351(1):157–168. doi:10.1016/j.cej.2018.06.101
   Google Scholar